Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), headquartered in Charlottesville, VA with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company innovating in the field of Alzheimer's disease (AD) and other neurodegenerative disorders. Acumen's core focus is on the development of novel, disease-modifying treatments by targeting toxic soluble amyloid-beta oligomers (AβOs), which are believed to be a primary underlying cause of AD. The company’s lead therapeutic candidate, sabirnetug (ACU193), is a humanized monoclonal antibody designed to selectively target these AβOs, thereby preventing synaptic dysfunction and neurodegeneration.
Acumen's scientific founders are pioneers in AβO research, contributing to decades of understanding in the field. This extensive research has culminated in the development of sabirnetug, which demonstrated positive topline results from the Phase 1 INTERCEPT-AD clinical trial. The trial showed that sabirnetug is well-tolerated, with a favorable safety profile, and demonstrated statistically significant, dose-related amyloid plaque reduction, validating its proof-of-mechanism.
Currently, Acumen is advancing sabirnetug into the Phase 2 ALTITUDE-AD trial, which aims to further evaluate its clinical efficacy and safety in early Alzheimer's disease. The company is also planning a Phase 1 study to explore a subcutaneous dosing option, enhancing patient accessibility and treatment convenience.
Acumen Pharmaceuticals remains committed to advancing its pioneering research into practical therapeutic solutions. The company's strategic partnerships, including a recent collaboration with Lonza for the manufacturing of sabirnetug, underscore its dedication to bringing effective treatments to market. With a strong financial footing, including $296.6 million in cash and marketable securities as of March 31, 2024, Acumen is well-positioned to support its clinical and operational activities into the first half of 2027.
Acumen’s mission is driven by the urgent need for safe and effective treatment options for Alzheimer's patients. Their work continues to be fueled by robust scientific insights and a commitment to improving the lives of those afflicted by AD.
Acumen Pharmaceuticals (NASDAQ: ABOS) has announced a virtual R&D Day scheduled for Oct. 2, 2024, at 10:00 a.m. ET. The event will focus on the company's strategic vision and the development of sabirnetug, their novel treatment for early Alzheimer's disease (AD) that targets toxic soluble amyloid beta oligomers (AβOs).
The webcast will feature Acumen's management and scientific leadership, along with external key opinion leaders including:
- Dr. Stephen Salloway, Director of the Memory and Aging Program at Butler Hospital and Professor at Brown University
- Dr. Paul Solomon, Founder of the Boston Center for Memory and investigator in the ongoing Phase 2 ALTITUDE-AD trial for sabirnetug
Participants can register for the live conference call and access the webcast through links provided. An archived version will be available on Acumen's website for at least one year.
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investor Conference. The company, which is developing a novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment, will engage in a fireside chat on Tuesday, Sept. 10, 2024, at 1:30 p.m. ET.
Investors and interested parties can access the live webcast of the fireside chat through the Investors tab on www.acumenpharm.com. The webcast will remain archived on the website for 90 days following the event, providing an opportunity for those unable to attend the live session to catch up on the discussion.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported its Q2 2024 financial results and business highlights. The company is actively enrolling subjects in ALTITUDE-AD, a Phase 2 study of sabirnetug (ACU193) for early Alzheimer's disease. In July 2024, Acumen dosed the first subject in a Phase 1 study for subcutaneous administration of sabirnetug, with topline results expected in Q1 2025. The company's cash position of $281.4 million as of June 30, 2024, is expected to support operations into H1 2027.
Financial highlights include:
- R&D expenses increased to $19.5 million in Q2 2024 from $9.1 million in Q2 2023
- G&A expenses rose to $4.8 million in Q2 2024 from $4.3 million in Q2 2023
- Net loss widened to $20.5 million in Q2 2024 from $11.6 million in Q2 2023
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing a novel therapeutic for Alzheimer's disease, has announced its plans to report second quarter 2024 financial results on August 13, 2024. The company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Interested parties can register for the live conference call using a provided link, which will furnish dial-in numbers and a PIN. Registration should be completed at least one day in advance. An archived version of the webcast will be available for a minimum of 30 days in the Investors section of Acumen's website.
Acumen Pharmaceuticals (NASDAQ: ABOS) has announced the dosing of the first subject in a Phase 1 study of subcutaneous sabirnetug (ACU193) for early Alzheimer's disease. The study aims to compare the pharmacokinetics between subcutaneous and intravenous administrations in healthy volunteers. Sabirnetug, co-formulated with Halozyme's ENHANZE® technology, targets soluble amyloid beta oligomers (AβOs) in the brain.
The subcutaneous formulation is designed to provide a more convenient and accessible option for patients, potentially improving treatment adherence. Acumen is also currently conducting the ALTITUDE-AD Phase 2 trial to evaluate the efficacy and safety of intravenous sabirnetug in early AD patients. Previous Phase 1 results showed favorable safety, target engagement, and amyloid plaque reduction comparable to approved therapies.
Acumen Pharmaceuticals (NASDAQ: ABOS) presented new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference 2024. The research focuses on patient experiences, biomarker data, and a new ultra-sensitive assay for measuring sabirnetug in cerebrospinal fluid. Sabirnetug, a humanized monoclonal antibody, targets toxic soluble amyloid beta oligomers (AβOs) in early symptomatic Alzheimer's disease (AD).
Key findings include:
- Patient interviews revealed desires for treatments that slow disease progression and maintain cognitive abilities
- Sabirnetug significantly lowered CSF levels of synaptic proteins, supporting its mechanism of action
- A new ultra-sensitive assay was developed to detect sabirnetug in CSF
Acumen is currently conducting the Phase 2 ALTITUDE-AD trial to further evaluate sabirnetug's efficacy and safety in early AD patients.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference (AAIC) 2024. The conference will be held in Philadelphia and online from July 28 to August 1, 2024. Sabirnetug, a humanized monoclonal antibody, has shown selective target engagement of toxic soluble amyloid beta oligomers (AβOs) in early symptomatic Alzheimer's disease (AD) patients. The company’s posters will discuss biomarker data, methods for detecting sabirnetug levels in cerebrospinal fluid (CSF), and patient experiences. The data aims to inform future clinical trials and potentially position sabirnetug as a best-in-class antibody treatment for early symptomatic AD.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported its Q1 2024 financial results and business highlights. The company announced the initiation of ALTITUDE-AD, a Phase 2 study of sabirnetug (ACU193) for early Alzheimer's disease, with the first patient dosed in May 2024. A Phase 1 study for a subcutaneous form of sabirnetug is expected in mid-2024. As of March 31, 2024, Acumen had $296.6 million in cash and equivalents, projected to fund operations into H1 2027. Financial results showed a net loss of $14.9 million, up from $11.3 million YoY. R&D expenses rose to $12.4 million from $8.7 million, while G&A expenses increased to $5.3 million from $4.4 million.
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The company focuses on developing therapeutics targeting toxic soluble amyloid beta oligomers for treating Alzheimer's disease. The management will join a fireside chat scheduled for May 20, 2024, at 12:30 p.m. ET. The event will be available via a live webcast on the company's investor relations page, with an archive accessible for 90 days.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will participate in the 2024 Bank of America Healthcare Conference to discuss their novel therapeutic for treating Alzheimer's disease. The event will take place on May 15, 2024, and can be accessed via a live webcast on their website.
FAQ
What is the current stock price of Acumen Pharmaceuticals (ABOS)?
What is the market cap of Acumen Pharmaceuticals (ABOS)?
What is Acumen Pharmaceuticals’ main focus?
What is sabirnetug (ACU193)?
What were the results of the Phase 1 INTERCEPT-AD trial?
What is the Phase 2 ALTITUDE-AD trial?
What are some recent achievements of Acumen Pharmaceuticals?
What is Acumen’s financial condition?
Where is Acumen Pharmaceuticals headquartered?
What is the significance of targeting amyloid-beta oligomers (AβOs)?
What future plans does Acumen Pharmaceuticals have for sabirnetug?
How can investors get more information about Acumen Pharmaceuticals?
